Journal of the International Child Neurology Association 2019-05-31T10:24:48+00:00 Professor Charles Newton Open Journal Systems <p>The Journal of the International Child Neurology Association (JICNA) is an Open Access Journal&nbsp;published by the International Child Neurology Association (ICNA), representing the Association’s official Journal. The journal aims to cover all sections of Child Neurology, Epilepsy, and Neuromuscular disorders, providing teaching, practical and professional support for clinicians dealing with neurological disorders in childhood. It publishes, after peer-review process papers concerning both clinical and basic research.</p> Optic neuritis associated with chronic inflammatory demyelinating polyneuropathy in a child - a case report 2019-05-31T10:24:48+00:00 Nigel Colin Griffith DR.NIGELGRIFFITH@GMAIL.COM <p class="p1"><span class="s1">Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder predominantly affecting the peripheral nervous system (PNS), characterised by muscle weakness and sensory disruption which may involve all four limbs[1]. CIDP affecting children is uncommon, with a large scale review in 2013 noting 143 documented cases described in the literature [2]. Central nervous system involvement has previously been described; however, optic neuropathy is an extremely rare manifestation of CIDP, with only a small number of cases previously reported (both unilateral and bilateral) in adult patients[3-5]. This report details a child who developed optic neuropathy in association with CIDP.<span class="Apple-converted-space">&nbsp;</span></span></p> 2019-05-31T10:24:22+00:00 ##submission.copyrightStatement## Cannabis and related products in the treatment of epilepsy 2019-05-31T04:10:05+00:00 J Helen Cross <p>There has been much recent heightened interest in the possible use of cannabinoid products in the treatment of complex epilepsies. Although systematic studies have now been performed and reported showing benefit of cannabidiol as Epidiolex (GW Pharma) in the treatment of Dravet and Lennox Gastaut syndromes, there remains much confusion with the role of hemp oils and other products for which there is no consistent product or evidence base for use. There is also much debate as to whether the psychoactive component, tetrahydrocannabinol is required for optimal effect, with no sound evidence base for support. The current position is that that data has been acquired for Epidiolex, and licence for use granted by the Federal Drug Administration, with data submitted to the European Medicines Authority. We await full licence and availability to enable prescription as a further therapeutic option for the complex developmental epileptic encephalopathies.&nbsp;</p> 2019-05-30T14:55:36+00:00 ##submission.copyrightStatement##